Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cessatech ASXSAT:CESSA -5.21%19 EV-to-OCF is -13.10 as of Sep. 20, 2026. GuruFocus rates XSAT:CESSA with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, Cessatech AS ranks better than 71.19% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cessatech AS's Enterprise Value is kr163.73 Mil.
Cessatech AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr-12.50 Mil. Therefore, Cessatech AS's EV-to-OCF for today is -13.10.
The historical rank and industry rank for Cessatech AS's EV-to-OCF or its related term are showing as below:
XSAT:CESSA'
s EV-to-OCF Range Over the Past 10 Years
Min: -29.18 Med: -20.31 Max: -10.56
Current: -10.83
During the past 6 years, the highest EV-to-OCF of Cessatech AS was -10.56. The lowest was -29.18. And the median was -20.31.
XSAT:CESSA's EV-to-OCF is ranked better than 71.19% of 1406
companies
in the Biotechnology industry
Industry Median: -3.37
vs XSAT:CESSA: -10.83
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cessatech AS's PE Ratio (TTM) for today is calculated as:
Cessatech AS's share price for today is kr9.10.
Cessatech AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.529.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cessatech AS EV-to-OCF Related Terms
Cessatech AS EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cessatech AS's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CESSA vs VRTX, REGN, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, Cessatech AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cessatech AS EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cessatech AS's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cessatech AS's EV-to-OCF falls into.
Cessatech AS's current Enterprise Value is kr163.73 Mil.
Cessatech AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-12.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cessatech AS (XSAT:CESSA) has a EV-to-OCF of -13.10 as of Sep. 20, 2026. According to the industry distribution chart, Cessatech AS ranks #405 out of 1406 companies in the Biotechnology industry, placing it in the top 28.8%.
Is Cessatech AS's EV-to-OCF too high?
Cessatech AS's current EV-to-OCF is -13.10. Based on the distribution chart, Cessatech AS ranks #405 out of 1406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cessatech AS has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cessatech AS ranks #405 out of 1406 companies for EV-to-OCF. This puts Cessatech AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Cessatech AS's current EV-to-OCF is -13.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (XSAT:CESSA) has a current EV-to-OCF of -13.10. The current EV-to-OCF is -13.10. Cessatech AS's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cessatech AS (XSAT:CESSA), the current EV-to-OCF is -13.10 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
19GF Score
Get the complete analysis for XSAT:CESSA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CESSA has been successfully added to your 
